Chair of the Medical Advisory Board, David is an experienced and accomplished medical professional specialising in Neuroscience Clinical Drug Development, Adult Psychiatry, Geriatric Psychiatry, Mood disorders and Schizophrenia.
David led a full drug discovery process from conception to approval for Esketamine, the world’s only legal psychedelic drug. This was during his time as Team Leader of the Esketamine Compound Development group for Janssen R&D (Spravato™).
David had a long, successful career at Johnson and Johnson, where he focussed on mental health issues. When not supporting Delica, he is currently based in the USA acting as Chief Medical Officer at PaxMedica, Inc.